X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with SUVEN LIFE - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs SUVEN LIFE - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA SUVEN LIFE AJANTA PHARMA/
SUVEN LIFE
 
P/E (TTM) x 28.6 20.2 142.1% View Chart
P/BV x 11.8 3.7 315.9% View Chart
Dividend Yield % 0.5 1.0 50.7%  

Financials

 AJANTA PHARMA   SUVEN LIFE
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
SUVEN LIFE
Mar-16
AJANTA PHARMA/
SUVEN LIFE
5-Yr Chart
Click to enlarge
High Rs1,720339 508.1%   
Low Rs1,103144 763.9%   
Sales per share (Unadj.) Rs194.639.2 495.9%  
Earnings per share (Unadj.) Rs45.27.5 606.0%  
Cash flow per share (Unadj.) Rs50.38.8 573.2%  
Dividends per share (Unadj.) Rs8.002.00 400.0%  
Dividend yield (eoy) %0.60.8 68.4%  
Book value per share (Unadj.) Rs132.049.0 269.5%  
Shares outstanding (eoy) m88.77127.28 69.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.36.2 117.9%   
Avg P/E ratio x31.232.4 96.5%  
P/CF ratio (eoy) x28.127.5 102.0%  
Price / Book Value ratio x10.74.9 216.9%  
Dividend payout %17.726.8 66.0%   
Avg Mkt Cap Rs m125,29930,732 407.7%   
No. of employees `000NA1.0 0.0%   
Total wages/salary Rs m2,570416 617.2%   
Avg. sales/employee Rs ThNM5,236.1-  
Avg. wages/employee Rs ThNM436.5-  
Avg. net profit/employee Rs ThNM995.5-  
INCOME DATA
Net Sales Rs m17,2754,995 345.8%  
Other income Rs m166194 85.9%   
Total revenues Rs m17,4425,189 336.1%   
Gross profit Rs m5,8071,233 471.1%  
Depreciation Rs m451167 269.5%   
Interest Rs m4954 90.2%   
Profit before tax Rs m5,4741,205 454.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,460255 572.5%   
Profit after tax Rs m4,014950 422.7%  
Gross profit margin %33.624.7 136.2%  
Effective tax rate %26.721.2 126.0%   
Net profit margin %23.219.0 122.2%  
BALANCE SHEET DATA
Current assets Rs m7,6394,986 153.2%   
Current liabilities Rs m2,7151,042 260.5%   
Net working cap to sales %28.579.0 36.1%  
Current ratio x2.84.8 58.8%  
Inventory Days Days4361 70.9%  
Debtors Days Days7939 201.0%  
Net fixed assets Rs m6,9143,126 221.2%   
Share capital Rs m177127 139.0%   
"Free" reserves Rs m11,4423,717 307.8%   
Net worth Rs m11,7216,236 187.9%   
Long term debt Rs m149432 34.4%   
Total assets Rs m14,8148,079 183.4%  
Interest coverage x112.923.2 486.3%   
Debt to equity ratio x00.1 18.3%  
Sales to assets ratio x1.20.6 188.6%   
Return on assets %27.412.4 220.7%  
Return on equity %34.215.2 224.9%  
Return on capital %46.518.9 246.5%  
Exports to sales %55.187.5 63.0%   
Imports to sales %6.012.2 49.1%   
Exports (fob) Rs m9,5274,371 218.0%   
Imports (cif) Rs m1,038611 169.9%   
Fx inflow Rs m10,4224,666 223.3%   
Fx outflow Rs m1,678942 178.1%   
Net fx Rs m8,7443,724 234.8%   
CASH FLOW
From Operations Rs m3,264922 354.0%  
From Investments Rs m-2,093-619 337.9%  
From Financial Activity Rs m-1,186-698 169.8%  
Net Cashflow Rs m-15-396 3.7%  

Share Holding

Indian Promoters % 73.8 63.4 116.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 0.0 -  
FIIs % 7.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 36.5 46.6%  
Shareholders   20,968 37,287 56.2%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   J.B.CHEMICALS  ALEMBIC LTD  CIPLA  CADILA HEALTHCARE  VENUS REMEDIES  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades on a Positive Note; Apollo Micro Systems IPO Lists at 74% Premium(11:30 am)

Stock markets in India are presently trading marginally higher. Sectoral indices are trading on a mixed note with stocks in the energy sector and IT sector witnessing maximum buying interest.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jan 22, 2018 01:37 PM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS